WASHINGTON (AP) — The Trump administration recently surprised many experts with its announcement to repurpose leucovorin, a generic drug, as a new treatment for autism. Dr. Richard Frye, who suggested the idea, expressed his astonishment that it was approved without extensive research. Critics have flagged the announcement as indicative of the administration's haphazard handling of autism treatment.
Leading autism organizations distanced themselves from the decision, with experts like psychiatrist David Mandell stating that current studies supporting leucovorin's efficacy are limited and unconvincing. We have nothing resembling even moderate evidence that leucovorin is an effective treatment for autism symptoms, Mandell commented.
Despite assertions from some parents about positive results with the drug, the prevailing view among researchers points to a genetic basis for autism, complicating discussions around treatment options. As advocates and researchers continue to navigate this controversial landscape, calls for more rigorous clinical trials become increasingly urgent.
Discussions over leucovorin's use were spurred by its potential link to folate metabolism, a critical aspect of prenatal development. However, the consensus remains that the evidence supporting its effectiveness remains fragile at best, risking the health of children if misused.
Having noted the increasing interest from parents, particularly through online forums, experts warn about the implications of unproven treatments becoming mainstream. Calls for a cautious and methodical approach are echoed by professionals advocating for proper clinical trials before wider acceptance.
